Opinion

Video

Post Hoc Analysis of ARANOTE; Ultra-Low PSA Responses

Research highlights the significant benefits of achieving ultra-low PSA levels in metastatic hormone-sensitive prostate cancer, delaying disease progression effectively.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Rationale for Ultra-Low PSA Threshold Analysis

      Key Themes:

      • Post hoc analysis focusing on PSA response thresholds
      • Particular focus on ultra-low PSA threshold (<0.02 ng/mL)
      • PSA as a surrogate biomarker in advanced prostate cancer

      Expert Insights:

      • Dr Shore explained the rationale for examining the ultra-low PSA threshold of <0.02 ng/mL in the ARANOTE trial.

      The discussion highlighted the historical relevance of low PSA levels in predicting treatment outcomes and the potential increased sensitivity of this threshold.

      Newsletter

      Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

      © 2025 MJH Life Sciences

      All rights reserved.